|
1. Marx RE. Pamidronate (Aredia) and zoledronate
(Zometa) induced avascular necrosis of the jaws: a
growing epidemic. J Oral Maxillofac
Surg. 2003;61:1115-7.
https://doi.org/10.1016/S0278-2391(03)00720-1
PMid:12966493
|
|
|
|
2. Gavaldá C, Bagan JV. Concept, diagnosis and
classification of bisphosphonate-associated osteonecrosis
of the jaws. A review of the literature. Med Oral Patol
Oral Cir Bucal. 2016;21:260-70.
https://doi.org/10.4317/medoral.21001
PMCid:PMC4867198
|
|
|
|
|
3. Bagan JV,
Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM,
Silvestre FJ, Scully CJ. Oral Pathol Med. 2005;34:120-3.
https://doi.org/10.1111/j.1600-0714.2004.00269.x
PMid:15641993
|
|
|
|
|
4. Sammut S, Malden N, Lopes V, Ralston S.
Epidemiological study of alendronate-related
osteonecrosis of the jaw in the southeast of Scotland. Br
J Oral Maxillofac Surg. 2016;54:501-5.
https://doi.org/10.1016/j.bjoms.2015.10.036
PMid:26975575
|
|
|
|
|
5. Khan A, Morrison A, Cheung A, Hashem W,
Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and
management in 2015. Osteoporos Int.
2016;27:853-9.
https://doi.org/10.1007/s00198-015-3335-3
PMid:26493811
|
|
|
|
|
6. Black D, Delmas P, Eastell R, et al.
Once-Yearly Zoledronic Acid for Treatment of
Postmenopausal Osteoporosis. The New England Journal of
Medicine. 2007;18:1809-22.
https://doi.org/10.1056/NEJMoa067312
PMid:17476007
|
|
|
|
|
7. Katz J, Ordoveza PA. Bisphosphonate-related
osteonecrosis of the jaw (BRONJ) associated with a
once-yearly IV infusion of zoledronic acid (Reclast) 5
mg: two cases and review of the literature. Quintessence
Int. 2014;45:685-90.
PMid:25019116
|
|
|
|
|
8. Lee CY, Suzuki JB. Medication-related
osteonecrosis of the jaws from once per year intravenous
zoledronic acid (Reclast): report of 4 cases. Implant
Dent. 2015;24:227-31.
https://doi.org/10.1097/ID.0000000000000227
PMid:25734948
|
|
|
|
|
9. Ruggiero SL, Dodson TB, Fantasia J, Goodday R,
Aghaloo T, Mehrotra B, O'Ryan F American association of
oral and maxillofacial surgeons position paper on
medication-related osteonecrosis of the jaw-2014 update. J
Oral Maxillofac Surg. 2014;72:1938-56.
https://doi.org/10.1016/j.joms.2014.04.031
PMid:25234529
|
|
|
|
|
10. Alhussain A, Peel S, Dempster L, Clokie C,
Azarpazhooh A. Knowledge, practices, and opinions of
Ontario dentists when treating patients receiving
bisphosphonates. J Oral Maxillofac
Surg. 2015;73:1095-105.
https://doi.org/10.1016/j.joms.2014.12.040
PMid:25843818
|
|
|
|
|
11. Ruggiero SL, Dodson TB, Assael LA, Landesberg
R, Marx RE, Mehrotra B. American Association of Oral and
Maxillofacial Surgeons position paper on
bisphosphonate-related osteonecrosis of the jaws–2009
update. J Oral Maxillofac Surg.
2009;67:2-12.
PMid:19371809
|
|
|
|
|
12. López-Jornet P, Camacho-Alonso F,
Molina-Mi-ano F, Gomez-Garcia F.
Bisphosphonate-associated osteonecrosis of the jaw.
Knowledge and attitudes of dentists and dental students:
a preliminary study. J Eval Clin Pract. 2010;16:878-82.
https://doi.org/10.1111/j.1365-2753.2009.01203.x
PMid:20663005
|
|
|
|
|
13. de Lima PB,
Brasil VL, de Castro JF, de Moraes Ramos-Perez FM, Alves
FA, dos Anjos Pontual ML, da Cruz Perez DE. Knowledge and attitudes of
Brazilian dental students and dentists regarding
bisphosphonate-related osteonecrosis of the jaw. Support
Care Cancer. 2015;23:3421-6.
https://doi.org/10.1007/s00520-015-2689-6
PMid:25757408
|
|